We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Optimer Pharmaceuticals, Inc.'s financial performance into perspective.
Archived Events: Optimer 2011 Investor Reception,
Chapter Links
Forward Looking Statements Disclaimer Pedro Lichtinger, President and CEO: Introductions and Comments on DIFICID Launch Greg Papaz, Senior Vice President, U.S. Commercial Operations: DIFICID Long Term Care Strategy Glenn S. Tillotson, PhD, Senior Vice President, Medical Affairs: CDAD Patient Management and Role of Risk Factors in ?Treating Disease Sherwood L. Gorbach, MD, Chief Scientific Officer and Senior Vice President, Research and Development: Review of Recent DIFICID Publications and Presentations Roy F. Chemaly, MD, MPH, Director, Infection Control; Director Antimicrobial Stewardship Program and Associate Professor of Medicine, MD Anderson Cancer Center: C. difficile Infections in Cancer Patients Hemal Shah, PharmD, Senior Vice President, Health Economics & Outcome Research and New Products Marketing: Demonstrating the Value of DIFICID Question & Answer Session
Recent Releases
May 16, 2012 Analysis of Data from Two Phase 3 Studies Shows DIFICID® Offered Faster Diarrheal Symptom Improvement than Oral Vancomycin in Patients with Cancer Being Treated for Clostridium difficile-Associated Diarrhea (CDAD)
May 10, 2012 Optimer Pharmaceuticals Reports First Quarter 2012 Financial Results
View all releases »
Investor Relations Contact
David A. Walseyir@optimerpharma.com
